Mibolerone (Cheque Drops)Tablet 500mcg x 100tabs
Mibolerone (Check Drops)
Anabolic / Androgenic ratio: 590/250 4,100 / 1,200
Effective intake (male) 500-5000 mcg / day
Effective intake (female) Not recommended
Duration: 4 hours
Detection period: Immediately after administration
Mibolerone (Cheque Drops)Tablet
500mcg /Tablet X 100 tablets
EffectiveDose:0.5-5mg
Anabollc/AndrogenicRatio:: 590:250
The Most Strongest Androgen Anabolics !!!
Under the brand name "Cheque Drops", Mibolerone was marketed as a veterinary drug by the Upjohn company.
Mibolerone is a potent anabolic steroid which is both higher affinity and more selective for the
androgen receptor than methyltrienolone.
Cheque Drops (Mibolerone) is an oral anabolic androgenic steroid derived from the anabolic
steroid Nandrolone. Specifically, this is a structurally altered form of Nandrolone. Cheque drops
exist by adding a methyl group to the 7th and 17th position of the Nandrolone hormone. The
added methyl group at the 7th position increases the hormone’s androgenicity and prevents the
action of the 5-alpha reductase enzyme. The added methyl group at the 17th position protects
the hormone’s oral ingestion. This classifies Cheque Drops as a C17-alpha alkylated (C17-aa)
anabolic steroid.
Cheque Drops are highly estrogenic. This anabolic steroid can cause a massive amount of
aromatase activity. It is also a very strong progestin. However, it is rarely used for long periods
of time or at doses that allow the estrogenic properties to be seen. It is due to the low amounts
used that the anabolic effects are almost never seen. It would take upwards of 5mg per day to
see a true anabolic effect that would in all likelihood produce significant estrogenic activity. Such
doses would also come with horrific side effects and consequences.
Mibolerone carry a half-life of approximately 3 hours.
Mibolerone can have the one of the strongest, negative impacts on liver enzymes of all C17-aa
steroids.
Although there is a negative point of it, it can greatly prevent the burden on the liver by using in
combination with a hepatoprotective agent.
